Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Authors:
Top Cited Papers
Open Access
- 23 November 2017
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 377 (21) , 2097-2099
Abstract
In the trials of the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program (Aug. 17 issue),1 patients who had been assigned to receive canagliflozin had significantly lower rates of the primary outcome (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) than those assigned to receive placebo (hazard ratio, 0.86; 95% confidence interval [CI], 0.75 to 0.97). Beyond statistical significance, however, a treatment difference must be clinically significant.2 On an absolute scale, these results show that more than 200 patients must receive daily canagliflozin for the duration of the trial (mean, 3.6 years; median, 2.4 years) in order for 1 patient to benefit. More importantly, the trials show a risk of amputation that is almost twice as high among patients receiving canagliflozin as among patients receiving placebo (hazard ratio, 1.97; 95% CI, 1.41 to 2.75). Although the risk was primarily at the level of the toes and metatarsals, 29% of the affected participants had a more proximal amputation. Similar to other new medications for type 2 diabetes, canagliflozin is expensive, with a suggested price per tablet of $10.53 (€9.09, £8.03).3 Economic models4,5 need to be updated to consider the benefit–harm ratio emerging from these new data.Keywords
This publication has 8 references indexed in Scilit:
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical TrialsAdvances in Therapy, 2017
- Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsDiabetes, Obesity and Metabolism, 2017
- The Primary Outcome Is Positive — Is That Good Enough?New England Journal of Medicine, 2016
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic controlJournal of Medical Economics, 2014
- Canagliflozin: Improving diabetes by making urine sweetCleveland Clinic Journal of Medicine, 2013
- Plasma Viscosity Increase with Progression of Peripheral Arterial Atherosclerotic DiseaseAngiology, 1996